Biocon Q2 FY26 Revenue Surges 20% Led by Strong Biosimilars Growth

reported a robust 20% year-on-year increase in consolidated revenue to ₹4,296 crore in Q2 FY26, primarily driven by significant expansion in its biosimilars segment, which grew 25% and contributed substantially to overall growth. The company’s operational leverage and improved product mix in biologics, alongside steady momentum in generics and research services, reinforced a strong quarter marked by a 29% rise in EBITDA and a 153% jump in profit before tax (excluding exceptional items). With continued focus on pipeline development and new product launches, Biocon is positioned to sustain its growth trajectory throughout the fiscal year.​ Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.